Chimeric Therapeutics CEO and Managing Director Jennifer Chow joined Steve Darling from Proactive to share news the company has highlighted the release of two CLTX CAR T abstracts for presentation at the Society for Neuro-Oncology . The highlight being positive results from Chimeric’s CLTX CAR T phase 1 clinical trial.
Chow telling Proactive that the initial abstract presentation of patients treated at the 1st dose level, a disease control rate of 75% was shown as 3 out of the 4 patients treated achieved a best response of stable disease assessed by RANO criteria. Additional details provided within the final presentation demonstrated that the disease control observed was durable for approximately 5-8 weeks. Chow also shared with Proactive The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022.